Tech Company Financing Transactions
Lyndra Therapeutics Funding Round
Lyndra Therapeutics, operating out of Watertown, secured $55 million in investment from Polaris Partners, Bill & Melinda Gates Foundation and Gilead Sciences.
Transaction Overview
Company Name
Announced On
1/30/2019
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series B
Investors
Proceeds Purpose
The funds will use for Phase II clinical trials, expansion of its Phase I pipeline and manufacturing scale-up.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
65 Grove St. 301
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Website
Email Address
Overview
Lyndra, Inc. develops a technology that extends oral drug delivery beyond one week. It develops oral sustained release formulations for pharmaceutical products. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Catherine Reynolds
Chairman
Amy Schulman
Chief Executive Officer
Patricia Hurter
Chief Medical Officer
Richard Scranton
Chief Operating Officer
Jessica Ballinger
Chief Technical Officer
Örn Almarsson
Co-Founder
Andrew Bellinger
Co-Founder
Robert Langer
Co-Founder
Giovanni Traverso
Vice President
Jennifer McGovern
VP - Bus. Development
Abigail Jenkins
VP - Engineering
Tyler Grant
VP - Finance
Dana Vittum
VP - Human Resources
Susan Birdsey
VP - Manufacturing
Raymond Knox
VP - Regulatory Affairs
Mary Christian
Browse more venture capital transactions:
Prev: 1/30/2019: Medigate venture capital transaction
Next: 1/31/2019: Moregidge venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs